Adverse Event (AE) Management With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the STRATUS(TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)

e264 at 1 mg/m , peripheral neuropathy of any grade(G) occured in 37,5%, G1 : 5 (15,6%) G2: 5 (15,6%) and G 3/4 : 2 (6,3 %) happening less commonly with subcutaneous infusion of Bortezomib. 08 patients had infectious pulmonary syndrome causing two deaths. 28 patients are alive: 04 pts in CR, 08 in VGPR and 10 in PR; 06 pts relapsed with median delay of 10 months (04-21). 07 pts died (21,9%) , one in CR, 4 after progression, one after severe neuropathy and one in VGPR after pulmonary infection. Anemia G4 seen in 3 pts (9,4%), Neutropenia G3 : 1 pt, Thrombocytopenia G2 : 3 pts. Other side effects included asthenia G2 and rarely diarrhea. Subcutaneous administration was locally very well tolerated. Median overall survival not reached; probability of survival 1⁄4 65 % at 16 months. Conclusion: In our practice, 41 % of patients are aged under 65 years; according to this observation, we can see that our population of myeloma is young and our results are encouraging; we hope soon to practice ASCT in our service to improve these results. 6. Multiple Myeloma Therapy Relapsed/Refractory Patients